This equated to an absolute benefit of 3.3 percentage points and a significant hazard ratio (HR) for recurrence or death of 0.748 in favor of the combination.

Here, we describe a small cohort of low recurrence score (RS) patients with early recurrence.

Authors: Lancelot Tremeau & Nicolas Mottet Abstract Following a treatment with curative intent, a biochemical recurrence may be diagnosed, often many years after the primary treatment.

Two MRD-positive patients were not diagnosed with clinical recurrence during the course of the study, one of whom has been lost to follow-up, they note. ctDNA detection was therefore 85.7% sensitive for the detection of any clinical recurrence and 100% sensitive for detection of metastatic recurrence, with a specificity of 97.4% for both types of recurrence.

Adjuvant everolimus may improve recurrence-free survival after nephrectomy in people with treatment-naïve renal cell carcinoma, particularly those with a very high risk for recurrence, suggest final results from the EVEREST trial.

The ABC trial has ruled out the adjuvant use of daily high-dose aspirin for the prevention of breast cancer recurrence in people with high-risk, HER2-negative disease.

Taking nonselective, but not selective, beta blockers at the time of radical prostatectomy may decrease the risk for prostate cancer recurrence, findings indicate.

People with EGFR -positive non-small-cell lung cancer may benefit from individualized risk-profiling, say researchers who observed a high recurrence risk following resection but also identified a subgroup that may be cured without adjuvant osimertinib.

Atezolizumab treatment also significantly reduced the risk for recurrence or death by 21% relative to BSC among all patients with stage II–IIIA disease, with respective median DFS times of 42.3 and 35.3 months, and 24- and 36-month DFS rates of 70.2% versus 61.6% and 55.7% versus 49.4%, respectively.

Tumor size and grade are the strongest predictors of long-term distant recurrence free survival in people with lymph node-negative, estrogen receptor-positive, HER2-negative breast cancer, show 25-year data from the STO-3 trial.

Judy Garber reports on the phase 3 OlympiA study suggesting that adjuvant olaparib could be an option for the treatment of patients with early-stage breast cancer and germline BRCA variants.

Black women with breast cancer are more likely than non-Hispanic White women to have a high-risk 21-gene Oncotype DX Breast Recurrence Score, and are more likely to die of breast cancer than their non-Hispanic White counterparts with a comparable score, US research shows.

Adjuvant treatment with osimertinib substantially reduces the risk for central nervous system recurrence among patients with resected stage IB–IIIA EGFR -mutated non-small-cell lung cancer, shows an analysis of phase 3 study data.

Long-term ipsilateral breast tumor recurrence rates are similar whether women are treated with accelerated partial-breast irradiation or whole-breast irradiation, results of the phase 3 APBI-IMRT-Florence trial show.

The presence of circulating tumor DNA and circulating tumor cells in postsurgical samples is associated with relapse and poor outcomes in early-stage triple-negative breast cancer patients with an incomplete pathologic response to neoadjuvant chemotherapy, research suggests.

68 Ga-prostate-specific membrane antigen-11 should be the “tracer of choice” for PET–CT to detect the postoperative biochemical recurrence of prostate cancer, say researchers who conducted a comparative imaging trial.

Men with localized prostate cancer and high-risk biochemical recurrence benefit from treatment with enzalutamide, either alongside leuprolide or alone.

Muscle-invasive bladder cancer patients with a nomogram-derived 1-year recurrence probability of at least 40% are likely to benefit from adjuvant chemotherapy, suggests a retrospective study.

“These findings support our hypothesis that the I-SABR strategy of combining immunotherapy with the immune-galvanising effects of SABR can reduce recurrence and increase cure rates,” write the study authors.

The researchers note that only one of the 24 patients with recurrence who underwent repeat biopsy had acquired a T790M mutation.